Contact PI/Project LeaderANDERSEN, KRISTIAN GRAUGAARD
Awardee OrganizationSCRIPPS RESEARCH INSTITUTE, THE
Description
Abstract Text
Project Summary/Abstract
The Ebola epidemic that ravaged West Africa from 2013 to 2016 is by far the largest outbreak ever recorded.
Weak healthcare infrastructure, community resistance, and a slow uncoordinated response, allowed the
epidemic to spin out of control. The region, however, is no stranger to dealing with viral hemorrhagic fevers.
Lassa fever is caused by infection with Lassa virus and is hyper-endemic in West Africa. Lassa fever is similar
to Ebola in that infection with Lassa virus can lead to a severe hemorrhagic fever. Infections with both Lassa
virus and Ebola virus can lead to deaths in more than 70% of hospitalized patients.
It is estimated that tens of thousands of people die from Lassa fever each year. These numbers are likely
underestimates, as the healthcare infrastructure in the affected countries is extremely weak, surveillance
almost non-existent, and most patients never present in the hospital. Despite the high case fatality rates of
hospitalized Ebola and Lassa fever patients, however, some people appear to be able to quickly fight the
viruses, whereas others die quickly from infection. Yet, what distinguishes fatal from non-fatal disease and the
development of symptomatic versus asymptomatic infection, remain largely unknown and severely
understudied. The goal of the Consortium for Viral Systems Biology is to uncover the virus and human factors
that determine how infected individuals are able to better fight the viruses. We will achieve this goal by
investigating the following three broad aims:
Aim 1. Define virus and host factors responsible for survival and non-survival in Ebola and Lassa fever
patients.
Aim 2. Identify factors that play roles in the development of severe long-term symptoms in survivors.
Aim 3. Define factors that determine whether human individuals develop symptomatic or asymptomatic
disease.
We will accomplish these aims by applying several ‘omics’ technologies, physiological measurements, and
high-throughput experimental approaches to unique patient and survivor cohorts of Lassa fever and Ebola.
We will develop novel predictive statistical models for identifying critical disease correlates and analyze
large-scale data sets to pinpoint causal host-pathogen interactions. By elucidation the molecular networks
that play critical roles in patient outcomes, this research will allow us to identify new targets for medicines and
vaccines and inform personalized treatment strategies. Our study will also provide novel research frameworks
and computational algorithms applicable to a wide range of other human pathogens.
Public Health Relevance Statement
Project Narrative
Lassa and Ebola viruses are two of the most devastating human pathogens, yet some individuals are better
able to fight infection than others. We will perform system-wide analyses of host and virus factors that
contribute to the severity of human disease and clinical outcome. By creating large integrated data sets of
genetic, immunological, biological, microbial, functional, and physiological features, we will build
sophisticated predictive models that will reveal the molecular interactions underlying successful clearance of
Lassa and Ebola viruses.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
781613492
UEI
PHZJFZ32NKH4
Project Start Date
01-February-2018
Project End Date
31-January-2023
Budget Start Date
01-February-2020
Budget End Date
31-January-2021
Project Funding Information for 2021
Total Funding
$450,000
Direct Costs
$300,421
Indirect Costs
$149,579
Year
Funding IC
FY Total Cost by IC
2021
National Institute of Allergy and Infectious Diseases
$450,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3U19AI135995-03S3
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3U19AI135995-03S3
Patents
No Patents information available for 3U19AI135995-03S3
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3U19AI135995-03S3
Clinical Studies
No Clinical Studies information available for 3U19AI135995-03S3
News and More
Related News Releases
No news release information available for 3U19AI135995-03S3
History
No Historical information available for 3U19AI135995-03S3
Similar Projects
No Similar Projects information available for 3U19AI135995-03S3